VRC EBOADC069 00 VP

Drug Profile

VRC EBOADC069 00 VP

Alternative Names: Bivalent Ebola adenoviral vector vaccine - NIAID/Okairos; Bivalent Ebola adenoviral vector vaccine - Okairos/NIAID; Bivalent Ebola vaccine - NIAID/Okairos; Bivalent Ebola vaccine - Okairos/NIAID; Bivalent Ebola virus vaccine - NIAID/Okairos; Bivalent Ebola virus vaccine - Okairos/NIAID; cAd3 EBO - NIAID/Okairos; cAd3-EBO - Okairos/NIAID; chAd-EBOV - NIAID/Okairos; VRC-EBOADC069-00-VP

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Okairos
  • Developer National Institute of Allergy and Infectious Diseases; University of Maryland, Baltimore
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 05 Apr 2017 National Institute of Allergy and Infectious Diseases completes a phase I trial for Ebola virus infections (In volunteers, Prevention, In adults) in USA (NCT02231866)
  • 24 Feb 2015 University of Maryland plans a phase Ib trial for Ebola virus infections (In volunteers, Prevention) in Mali (NCT02368119)
  • 01 Jan 2015 Phase-I clinical trials in Ebola virus infections (Prevention, In volunteers) in Uganda (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top